Latest Insider Transactions at Bio Techne Corp (TECH)
This section provides a real-time view of insider transactions for Bio Techne Corp (TECH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIO-TECHNE Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIO-TECHNE Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 25
2025
|
Roeland Nusse Director |
SELL
Open market or private sale
|
Direct |
17,040
-27.66%
|
$954,240
$56.36 P/Share
|
|
Aug 25
2025
|
Roeland Nusse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,040
+21.67%
|
$357,840
$21.84 P/Share
|
|
Aug 25
2025
|
Robert V Baumgartner Director |
SELL
Open market or private sale
|
Direct |
17,040
-27.53%
|
$954,240
$56.21 P/Share
|
|
Aug 25
2025
|
Robert V Baumgartner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,040
+21.59%
|
$357,840
$21.84 P/Share
|
|
Aug 15
2025
|
James Hippel CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,926
-1.46%
|
$102,078
$53.6 P/Share
|
|
Aug 15
2025
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,010
+2.95%
|
-
|
|
Aug 15
2025
|
William Geist PRESIDENT, PROTEIN SCIENCES |
SELL
Payment of exercise price or tax liability
|
Direct |
803
-5.05%
|
$42,559
$53.6 P/Share
|
|
Aug 15
2025
|
William Geist PRESIDENT, PROTEIN SCIENCES |
BUY
Exercise of conversion of derivative security
|
Direct |
2,623
+14.15%
|
-
|
|
Aug 15
2025
|
Matthew Mc Manus President - Diag & Spatial Bio |
SELL
Payment of exercise price or tax liability
|
Direct |
880
-15.67%
|
$46,640
$53.6 P/Share
|
|
Aug 15
2025
|
Matthew Mc Manus President - Diag & Spatial Bio |
BUY
Exercise of conversion of derivative security
|
Direct |
2,637
+31.96%
|
-
|
|
Aug 15
2025
|
Shane Bohnen SVP - General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
527
-10.73%
|
$27,931
$53.6 P/Share
|
|
Aug 15
2025
|
Shane Bohnen SVP - General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,718
+25.91%
|
-
|
|
Aug 15
2025
|
Kim Kelderman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,305
-7.79%
|
$228,165
$53.6 P/Share
|
|
Aug 15
2025
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,543
+13.39%
|
-
|
|
Aug 15
2025
|
Amy E. Herr Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
101
-4.48%
|
$5,353
$53.6 P/Share
|
|
Aug 15
2025
|
Amy E. Herr Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
279
+11.01%
|
-
|
|
Aug 07
2025
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,040
+7.17%
|
$105,840
$21.84 P/Share
|
|
Jul 29
2025
|
James Hippel CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
147,431
-53.57%
|
$8,550,998
$58.55 P/Share
|
|
Jul 29
2025
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
168,620
+37.99%
|
$7,419,280
$44.33 P/Share
|
|
Jul 22
2025
|
Kim Kelderman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
43,649
-48.3%
|
$2,313,397
$53.12 P/Share
|
|
Jul 22
2025
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
48,176
+34.77%
|
$2,119,744
$44.33 P/Share
|
|
Jul 15
2025
|
Kim Kelderman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,933
-43.83%
|
$1,679,583
$51.42 P/Share
|
|
Jul 15
2025
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,132
+32.47%
|
$1,589,808
$44.33 P/Share
|
|
Jun 09
2025
|
Amy E. Herr Director |
SELL
Open market or private sale
|
Indirect |
1,280
-39.31%
|
$62,720
$49.77 P/Share
|
|
Jun 09
2025
|
Amy E. Herr Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,280
+28.22%
|
$56,320
$44.33 P/Share
|
|
May 01
2025
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+16.62%
|
$252,000
$21.84 P/Share
|
|
Apr 03
2025
|
Shane Bohnen SVP - General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
747
-18.95%
|
$40,338
$54.86 P/Share
|
|
Apr 03
2025
|
Shane Bohnen SVP - General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,260
+36.45%
|
-
|
|
Feb 14
2025
|
Amy E. Herr Director |
SELL
Open market or private sale
|
Indirect |
1,860
-48.49%
|
$120,900
$65.96 P/Share
|
|
Feb 14
2025
|
Amy E. Herr Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,976
+34.0%
|
$86,944
$44.33 P/Share
|
|
Feb 03
2025
|
Amy E. Herr Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,040
+50.0%
|
-
|
|
Feb 01
2025
|
Matthew Mc Manus President - Diag & Spatial Bio |
SELL
Payment of exercise price or tax liability
|
Direct |
1,642
-35.54%
|
$119,866
$73.55 P/Share
|
|
Feb 01
2025
|
Matthew Mc Manus President - Diag & Spatial Bio |
BUY
Exercise of conversion of derivative security
|
Direct |
4,620
+50.0%
|
-
|
|
Feb 01
2025
|
William Geist PRESIDENT, PROTEIN SCIENCES |
SELL
Payment of exercise price or tax liability
|
Direct |
1,109
-7.7%
|
$80,957
$73.55 P/Share
|
|
Feb 01
2025
|
William Geist PRESIDENT, PROTEIN SCIENCES |
BUY
Exercise of conversion of derivative security
|
Direct |
3,320
+18.73%
|
-
|
|
Jan 27
2025
|
Kim Kelderman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,392
-13.24%
|
$1,031,184
$77.57 P/Share
|
|
Jan 27
2025
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,392
+20.36%
|
$495,504
$37.7 P/Share
|
|
Nov 01
2024
|
James Hippel CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,475
-5.73%
|
$485,625
$75.31 P/Share
|
|
Nov 01
2024
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,159
+10.42%
|
-
|
|
Nov 01
2024
|
Kim Kelderman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,430
-5.86%
|
$182,250
$75.31 P/Share
|
|
Nov 01
2024
|
William Geist PRESIDENT, PROTEIN SCIENCES |
SELL
Payment of exercise price or tax liability
|
Direct |
3,270
-22.79%
|
$245,250
$75.31 P/Share
|
|
Nov 01
2024
|
William Geist PRESIDENT, PROTEIN SCIENCES |
BUY
Exercise of conversion of derivative security
|
Direct |
9,912
+40.85%
|
-
|
|
Oct 24
2024
|
Robert V Baumgartner Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+3.16%
|
-
|
|
Oct 24
2024
|
Judith V Klimovsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+40.57%
|
-
|
|
Oct 24
2024
|
Alpna Seth Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+9.6%
|
-
|
|
Oct 24
2024
|
Roeland Nusse Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+3.18%
|
-
|
|
Oct 24
2024
|
John L Higgins Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+2.94%
|
-
|
|
Oct 24
2024
|
Julie L Bushman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+17.01%
|
-
|
|
Oct 24
2024
|
Rupert Vessey Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+13.53%
|
-
|
|
Oct 24
2024
|
Joseph D Keegan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,462
+9.6%
|
-
|